An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-04

AUTHORS

I Kümler, R L Eefsen, Peter Grundtvig Sørensen, S Theile, A Fullerton, P G Nielsen, Benny Vittrup Jensen, D L Nielsen

ABSTRACT

PURPOSE: Oral administration of chemotherapy offers several advantages in comparison with intravenous administration. Previously, data on a new oral formulation of irinotecan have been published. The aim of the present study was to evaluate the safety, tolerability, and Maximum Tolerated Dose (MTD) of the new oral irinotecan formulation in combination with oral capecitabine. METHODS: The study was an open label, phase 1, single center, extension part in which oral irinotecan was investigated in combination with capecitabine. The MTD of irinotecan in combination with capecitabine was 17.5 mg/m2 once daily for 14 consecutive days in combination with capecitabine 800 mg/m2 twice daily. Eligible patients were adults with metastatic or unresectable solid tumors for which no standard curative or palliative therapies existed. RESULTS: 14 patients were included in the extension part. No grade 3 or 4 hematologic toxicities were observed. Non-hematological toxicities included grade 1 and 2 diarrhea, fatigue, cholinergic syndrome, vomiting, and weight loss. Totally, 3 grade 3 toxicities and no grade 4 event were reported. No objective responses were observed. Five patients had stable disease lasting median 14 weeks. CONCLUSIONS: Capecitabine in combination with oral irinotecan could be a new treatment option offering a more convenient and patient friendly treatment strategy compared to intravenous irinotecan. The combination is fairly tolerated; however, further investigations are needed to assess the efficacy of this regimen. More... »

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-019-03819-0

DOI

http://dx.doi.org/10.1007/s00280-019-03819-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113185174

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30949758


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark. ibekml01@regionh.dk."
          ], 
          "type": "Organization"
        }, 
        "familyName": "K\u00fcmler", 
        "givenName": "I", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eefsen", 
        "givenName": "R L", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "S\u00f8rensen", 
        "givenName": "Peter Grundtvig", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Theile", 
        "givenName": "S", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Oncoral Pharma ApS, c/o Jusmedico, Kongevejen 371, Holte, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fullerton", 
        "givenName": "A", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Oncoral Pharma ApS, c/o Jusmedico, Kongevejen 371, Holte, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nielsen", 
        "givenName": "P G", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jensen", 
        "givenName": "Benny Vittrup", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gentofte Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411646.0", 
          "name": [
            "Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nielsen", 
        "givenName": "D L", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-004-0874-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007848801", 
          "https://doi.org/10.1007/s00280-004-0874-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdl071", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008381637"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-012-9824-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010172644", 
          "https://doi.org/10.1007/s10637-012-9824-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-012-9824-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010172644", 
          "https://doi.org/10.1007/s10637-012-9824-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-14-986", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015583184", 
          "https://doi.org/10.1186/1471-2407-14-986"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e31804b40bb", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022936341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e31804b40bb", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022936341"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-05-2368", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024763018"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-010-9528-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026463355", 
          "https://doi.org/10.1007/s10637-010-9528-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu260", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029291056"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds122", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033567728"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mcg.0b013e3182470f09", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037963679"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mcg.0b013e3182470f09", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037963679"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-198212000-00014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045278392"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-198212000-00014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045278392"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv295", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045601700"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834009355164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077267"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834009355164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077267"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077675908", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw350", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079330788"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4143/crt.2017.562", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101054104"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4143/crt.2017.562", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101054104"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30140-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101553187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30140-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101553187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30140-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101553187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-018-3720-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109785986", 
          "https://doi.org/10.1007/s00280-018-3720-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-018-3720-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109785986", 
          "https://doi.org/10.1007/s00280-018-3720-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-018-3720-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109785986", 
          "https://doi.org/10.1007/s00280-018-3720-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-018-3720-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109785986", 
          "https://doi.org/10.1007/s00280-018-3720-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-04", 
    "datePublishedReg": "2019-04-04", 
    "description": "PURPOSE: Oral administration of chemotherapy offers several advantages in comparison with intravenous administration. Previously, data on a new oral formulation of irinotecan have been published. The aim of the present study was to evaluate the safety, tolerability, and Maximum Tolerated Dose (MTD) of the new oral irinotecan formulation in combination with oral capecitabine.\nMETHODS: The study was an open label, phase 1, single center, extension part in which oral irinotecan was investigated in combination with capecitabine. The MTD of irinotecan in combination with capecitabine was 17.5\u00a0mg/m2 once daily for 14 consecutive days in combination with capecitabine 800\u00a0mg/m2 twice daily. Eligible patients were adults with metastatic or unresectable solid tumors for which no standard curative or palliative therapies existed.\nRESULTS: 14 patients were included in the extension part. No grade 3 or 4 hematologic toxicities were observed. Non-hematological toxicities included grade 1 and 2 diarrhea, fatigue, cholinergic syndrome, vomiting, and weight loss. Totally, 3 grade 3 toxicities and no grade 4 event were reported. No objective responses were observed. Five patients had stable disease lasting median 14 weeks.\nCONCLUSIONS: Capecitabine in combination with oral irinotecan could be a new treatment option offering a more convenient and patient friendly treatment strategy compared to intravenous irinotecan. The combination is fairly tolerated; however, further investigations are needed to assess the efficacy of this regimen.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-019-03819-0", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }
    ], 
    "name": "An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine.", 
    "productId": [
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30949758"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-019-03819-0"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113185174"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-019-03819-0", 
      "https://app.dimensions.ai/details/publication/pub.1113185174"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000372_0000000372/records_117100_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s00280-019-03819-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03819-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03819-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03819-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03819-0'


 

This table displays all metadata directly associated to this object as RDF triples.

162 TRIPLES      20 PREDICATES      42 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-019-03819-0 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N0fd3b5772824483b812c5dadb61f8679
4 schema:citation sg:pub.10.1007/s00280-004-0874-2
5 sg:pub.10.1007/s00280-018-3720-7
6 sg:pub.10.1007/s10637-010-9528-x
7 sg:pub.10.1007/s10637-012-9824-8
8 sg:pub.10.1186/1471-2407-14-986
9 https://app.dimensions.ai/details/publication/pub.1077675908
10 https://doi.org/10.1016/s1470-2045(18)30140-2
11 https://doi.org/10.1093/annonc/mdl071
12 https://doi.org/10.1093/annonc/mds122
13 https://doi.org/10.1093/annonc/mdu260
14 https://doi.org/10.1093/annonc/mdv295
15 https://doi.org/10.1093/annonc/mdw350
16 https://doi.org/10.1097/00000421-198212000-00014
17 https://doi.org/10.1097/coc.0b013e31804b40bb
18 https://doi.org/10.1097/mcg.0b013e3182470f09
19 https://doi.org/10.1158/1078-0432.ccr-05-2368
20 https://doi.org/10.1177/1758834009355164
21 https://doi.org/10.4143/crt.2017.562
22 schema:datePublished 2019-04-04
23 schema:datePublishedReg 2019-04-04
24 schema:description PURPOSE: Oral administration of chemotherapy offers several advantages in comparison with intravenous administration. Previously, data on a new oral formulation of irinotecan have been published. The aim of the present study was to evaluate the safety, tolerability, and Maximum Tolerated Dose (MTD) of the new oral irinotecan formulation in combination with oral capecitabine. METHODS: The study was an open label, phase 1, single center, extension part in which oral irinotecan was investigated in combination with capecitabine. The MTD of irinotecan in combination with capecitabine was 17.5 mg/m2 once daily for 14 consecutive days in combination with capecitabine 800 mg/m2 twice daily. Eligible patients were adults with metastatic or unresectable solid tumors for which no standard curative or palliative therapies existed. RESULTS: 14 patients were included in the extension part. No grade 3 or 4 hematologic toxicities were observed. Non-hematological toxicities included grade 1 and 2 diarrhea, fatigue, cholinergic syndrome, vomiting, and weight loss. Totally, 3 grade 3 toxicities and no grade 4 event were reported. No objective responses were observed. Five patients had stable disease lasting median 14 weeks. CONCLUSIONS: Capecitabine in combination with oral irinotecan could be a new treatment option offering a more convenient and patient friendly treatment strategy compared to intravenous irinotecan. The combination is fairly tolerated; however, further investigations are needed to assess the efficacy of this regimen.
25 schema:genre research_article
26 schema:inLanguage en
27 schema:isAccessibleForFree false
28 schema:isPartOf sg:journal.1088364
29 schema:name An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine.
30 schema:productId N1d82b8303cf04aee8f1cd3fdcd6d085d
31 N3fe8d26996bb45c9abe882207defd131
32 N93592058821d4ab3af7f27b23d2c1915
33 Ndee947e2b61547c082d54656291bafe5
34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113185174
35 https://doi.org/10.1007/s00280-019-03819-0
36 schema:sdDatePublished 2019-04-11T14:18
37 schema:sdLicense https://scigraph.springernature.com/explorer/license/
38 schema:sdPublisher N9cb30af663d54937a30a312d33fba278
39 schema:url http://link.springer.com/10.1007/s00280-019-03819-0
40 sgo:license sg:explorer/license/
41 sgo:sdDataset articles
42 rdf:type schema:ScholarlyArticle
43 N01e43c3558734c59b446ba148881b0ef rdf:first Ndf04695380bc477f90f647b95edfd6a0
44 rdf:rest N6a4c7976904c45d0acb1c783eb7a3f5d
45 N0236fb77620f4759a405b79d12ede57b schema:name Oncoral Pharma ApS, c/o Jusmedico, Kongevejen 371, Holte, Denmark.
46 rdf:type schema:Organization
47 N0fd3b5772824483b812c5dadb61f8679 rdf:first Ndaa84f67a324453b951316b4352ce1bd
48 rdf:rest N22b64dcb5adb433b86a35a59c5f02197
49 N1d82b8303cf04aee8f1cd3fdcd6d085d schema:name doi
50 schema:value 10.1007/s00280-019-03819-0
51 rdf:type schema:PropertyValue
52 N1f0e1049004445d88e0fc3d34823659d rdf:first N33a3f38ffaa04846a07287bf5cea1044
53 rdf:rest rdf:nil
54 N22b64dcb5adb433b86a35a59c5f02197 rdf:first N93ab397d235b4da88102f87e22f37aa4
55 rdf:rest Na30089f046cb4f64aa29a7d9a019b506
56 N33a3f38ffaa04846a07287bf5cea1044 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
57 schema:familyName Nielsen
58 schema:givenName D L
59 rdf:type schema:Person
60 N3fe8d26996bb45c9abe882207defd131 schema:name pubmed_id
61 schema:value 30949758
62 rdf:type schema:PropertyValue
63 N6a4c7976904c45d0acb1c783eb7a3f5d rdf:first Ne48089b2107b4348a4bea66636573971
64 rdf:rest N79350acaa0814e24b71d37b03b0e6d81
65 N79350acaa0814e24b71d37b03b0e6d81 rdf:first Nb6db565d93264ff5bdf2204adc096f07
66 rdf:rest N1f0e1049004445d88e0fc3d34823659d
67 N93592058821d4ab3af7f27b23d2c1915 schema:name dimensions_id
68 schema:value pub.1113185174
69 rdf:type schema:PropertyValue
70 N93ab397d235b4da88102f87e22f37aa4 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
71 schema:familyName Eefsen
72 schema:givenName R L
73 rdf:type schema:Person
74 N9cb30af663d54937a30a312d33fba278 schema:name Springer Nature - SN SciGraph project
75 rdf:type schema:Organization
76 N9fccc08301954348a87b578371957b64 schema:name Oncoral Pharma ApS, c/o Jusmedico, Kongevejen 371, Holte, Denmark.
77 rdf:type schema:Organization
78 Na30089f046cb4f64aa29a7d9a019b506 rdf:first Ncece6b1fba3b420bae11b0d3f4a0dd43
79 rdf:rest Ncd34ad5b796b476fa81577b3c914d380
80 Nb6db565d93264ff5bdf2204adc096f07 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
81 schema:familyName Jensen
82 schema:givenName Benny Vittrup
83 rdf:type schema:Person
84 Ncd34ad5b796b476fa81577b3c914d380 rdf:first Nff4c6f0751284e8faebe95afc6e32a6f
85 rdf:rest N01e43c3558734c59b446ba148881b0ef
86 Ncece6b1fba3b420bae11b0d3f4a0dd43 schema:affiliation https://www.grid.ac/institutes/grid.411646.0
87 schema:familyName Sørensen
88 schema:givenName Peter Grundtvig
89 rdf:type schema:Person
90 Ndaa84f67a324453b951316b4352ce1bd schema:affiliation https://www.grid.ac/institutes/grid.411646.0
91 schema:familyName Kümler
92 schema:givenName I
93 rdf:type schema:Person
94 Ndee947e2b61547c082d54656291bafe5 schema:name nlm_unique_id
95 schema:value 7806519
96 rdf:type schema:PropertyValue
97 Ndf04695380bc477f90f647b95edfd6a0 schema:affiliation N9fccc08301954348a87b578371957b64
98 schema:familyName Fullerton
99 schema:givenName A
100 rdf:type schema:Person
101 Ne48089b2107b4348a4bea66636573971 schema:affiliation N0236fb77620f4759a405b79d12ede57b
102 schema:familyName Nielsen
103 schema:givenName P G
104 rdf:type schema:Person
105 Nff4c6f0751284e8faebe95afc6e32a6f schema:affiliation https://www.grid.ac/institutes/grid.411646.0
106 schema:familyName Theile
107 schema:givenName S
108 rdf:type schema:Person
109 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
110 schema:name Medical and Health Sciences
111 rdf:type schema:DefinedTerm
112 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
113 schema:name Clinical Sciences
114 rdf:type schema:DefinedTerm
115 sg:journal.1088364 schema:issn 0344-5704
116 1432-0843
117 schema:name Cancer Chemotherapy and Pharmacology
118 rdf:type schema:Periodical
119 sg:pub.10.1007/s00280-004-0874-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007848801
120 https://doi.org/10.1007/s00280-004-0874-2
121 rdf:type schema:CreativeWork
122 sg:pub.10.1007/s00280-018-3720-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109785986
123 https://doi.org/10.1007/s00280-018-3720-7
124 rdf:type schema:CreativeWork
125 sg:pub.10.1007/s10637-010-9528-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1026463355
126 https://doi.org/10.1007/s10637-010-9528-x
127 rdf:type schema:CreativeWork
128 sg:pub.10.1007/s10637-012-9824-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010172644
129 https://doi.org/10.1007/s10637-012-9824-8
130 rdf:type schema:CreativeWork
131 sg:pub.10.1186/1471-2407-14-986 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015583184
132 https://doi.org/10.1186/1471-2407-14-986
133 rdf:type schema:CreativeWork
134 https://app.dimensions.ai/details/publication/pub.1077675908 schema:CreativeWork
135 https://doi.org/10.1016/s1470-2045(18)30140-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101553187
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1093/annonc/mdl071 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008381637
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1093/annonc/mds122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033567728
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1093/annonc/mdu260 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029291056
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1093/annonc/mdv295 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045601700
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1093/annonc/mdw350 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079330788
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1097/00000421-198212000-00014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045278392
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1097/coc.0b013e31804b40bb schema:sameAs https://app.dimensions.ai/details/publication/pub.1022936341
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1097/mcg.0b013e3182470f09 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037963679
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1158/1078-0432.ccr-05-2368 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024763018
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1177/1758834009355164 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064077267
156 rdf:type schema:CreativeWork
157 https://doi.org/10.4143/crt.2017.562 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101054104
158 rdf:type schema:CreativeWork
159 https://www.grid.ac/institutes/grid.411646.0 schema:alternateName Gentofte Hospital
160 schema:name Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark.
161 Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark. ibekml01@regionh.dk.
162 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...